ライフサイエンスコーパス: immunodeficiency syndrome

1 s against HIV, the culprit of AIDS (acquired immunodeficiency syndrome).

2 patients died (unrelated to HIV or acquired immunodeficiency syndrome).

3 mmunodeficiency virus (HIV) but not acquired immunodeficiency syndrome.

4 been identified in a patient with hyper-IgM immunodeficiency syndrome.

5 nts <350 cells/mm(3) and 2 (7%) had acquired immunodeficiency syndrome.

6 tically uncharacterized autoinflammatory and immunodeficiency syndrome.

7 rus (SIV)-infected macaque model of acquired immunodeficiency syndrome.

8 , tyrosine kinase 2, underlies another human immunodeficiency syndrome.

9 ed patients with cancer or advanced acquired immunodeficiency syndrome.

10 een found to cause the human severe combined immunodeficiency syndrome.

11 sease, and wasting associated with the human immunodeficiency syndrome.

12 ptoms), and deaths were ascribed to acquired immunodeficiency syndrome.

13 e, and human immunodeficiency virus/acquired immunodeficiency syndrome.

14 viral persistence in patients with acquired immunodeficiency syndrome.

15 DHPS mutations in 107 patients with acquired immunodeficiency syndrome.

16 pproved by the FDA for treatment of acquired immunodeficiency syndrome.

17 the context of immunodeficiency and acquired immunodeficiency syndrome.

18 eficiency virus (HIV) infection and acquired immunodeficiency syndrome.

19 irus infection and delayed onset of acquired immunodeficiency syndrome.

20 tive states, immune cytopenias, and acquired immunodeficiency syndrome.

21 een described only in patients with acquired immunodeficiency syndrome.

22 llite regions are characteristic for the ICF immunodeficiency syndrome.

23 I treatment adjunctively in HIV and acquired immunodeficiency syndrome.

24 ho family of GTPases associated with a human immunodeficiency syndrome.

25 unistic infections in patients with acquired immunodeficiency syndrome.

26 e vascular injury syndromes seen in acquired immunodeficiency syndrome.

27 tion, particularly in patients with acquired immunodeficiency syndrome.

28 m cell genesis in mice is mutated in a human immunodeficiency syndrome.

29 tion, muscle weakness, and a severe combined immunodeficiency syndrome.

30 thway as a genetic etiology for this primary immunodeficiency syndrome.

31 an, suggesting IKBKB K171R underlies a novel immunodeficiency syndrome.

32 Irgm1 deficiency is associated with a severe immunodeficiency syndrome.

33 STK4 deficiency is a novel human primary immunodeficiency syndrome.

34 ition of H3K4me3 is mutated in patients with immunodeficiency syndromes.

35 eads to various autoimmune, inflammatory and immunodeficiency syndromes.

36 mutants are also mutated in human inherited immunodeficiency syndromes.

37 cumented in the treatment of severe combined immunodeficiency syndromes.

38 ndrome, distinct from other types of HED and immunodeficiency syndromes.

39 lvin D1 in the treatment of XLP-2 and innate immunodeficiency syndromes.

40 lative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent confidence i

41 rson-years, 268 of 614 men incurred acquired immunodeficiency syndrome, 49 died, and 90 were lost to

42 nodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each).

43 Immunodeficiency syndromes (acquired/congenital/iatrogen

44 r infection and 5-year incidence of acquired immunodeficiency syndrome, adjusting for (continuous) ag

45 njection drug use on 6-year risk of acquired immunodeficiency syndrome (AIDS) after initiation of com

46 igate the validity of self-reported acquired immunodeficiency syndrome (AIDS) among women enrolled in

47 associations with incident clinical acquired immunodeficiency syndrome (AIDS) and CD4+ T cell count d

48 irus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between Ja

49 amatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS surv

50 myelinolysis), infections [malaria, acquired immunodeficiency syndrome (AIDS) and infection with huma

51 t a correlation between severity of acquired immunodeficiency syndrome (AIDS) and selenium deficiency

52 In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insidiously an

53 alitis and dementia associated with acquired immunodeficiency syndrome (AIDS) are characterized by le

54 sit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment.

55 A total of 1600 participants with acquired immunodeficiency syndrome (AIDS) but without CMV retinit

56 linical trial to assess the risk of acquired immunodeficiency syndrome (AIDS) by timing of therapy.

57 the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United Stat

58 stimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attributable to s

59 sent an increasing proportion of US acquired immunodeficiency syndrome (AIDS) cases, few research stu

60 for certain biliary diseases, e.g., acquired immunodeficiency syndrome (AIDS) cholangiopathy and graf

61 ryptosporidiosis is associated with acquired immunodeficiency syndrome (AIDS) cholangiopathy and occu

62 virus (HIV) infections and averting acquired immunodeficiency syndrome (AIDS) deaths in the San Franc

63 Declines in the number of acquired immunodeficiency syndrome (AIDS) deaths were first obser

64 urred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining.

65 gressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons

66 unodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has grown from

67 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is the difficu

68 ccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many ques

69 Early in the acquired immunodeficiency syndrome (AIDS) epidemic, epidemiologic

70 Persons with acquired immunodeficiency syndrome (AIDS) have a higher incidence

71 cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong

72 virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, efficiently

73 m sooty mangabeys, are the cause of acquired immunodeficiency syndrome (AIDS) in humans.

74 e 1 (HIV-1), the etiologic agent of acquired immunodeficiency syndrome (AIDS) in humans.

75 e focused on access to treatment of acquired immunodeficiency syndrome (AIDS) in poor, severely affec

76 ciency virus (HIV) infection or the acquired immunodeficiency syndrome (AIDS) in sub-Saharan Africa.

77 owever, SIVs do not generally cause acquired immunodeficiency syndrome (AIDS) in their natural hosts.

78 n is a key factor in progression to acquired immunodeficiency syndrome (AIDS) in untreated HIV-infect

79 Acquired immunodeficiency syndrome (AIDS) is principally a diseas

80 As people with acquired immunodeficiency syndrome (AIDS) live longer, the preval

81 a high viral set point progress to acquired immunodeficiency syndrome (AIDS) more rapidly than those

82 nderstand recent temporal trends in acquired immunodeficiency syndrome (AIDS) mortality in the era of

83 sk (RR) for clinical progression to acquired immunodeficiency syndrome (AIDS) of 1.66 (95% confidence

84 class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among patients in

85 ter or until the development of the acquired immunodeficiency syndrome (AIDS) or another condition th

86 e antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,498 US me

87 Rates of acquired immunodeficiency syndrome (AIDS) or death on suppressive

88 al therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while accounti

89 troviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the authors u

90 ly needed to curb the growth of the acquired immunodeficiency syndrome (AIDS) pandemic and ultimately

91 strategies that aim to contain the acquired immunodeficiency syndrome (AIDS) pandemic.

92 The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis is a progr

93 d populations compared with similar acquired immunodeficiency syndrome (AIDS) patients in the United

94 dy reports the surgical outcomes of acquired immunodeficiency syndrome (AIDS) patients with Cytomegal

95 ncers that occur at higher rates in acquired immunodeficiency syndrome (AIDS) patients, the cancer ex

96 and drives systemic inflammation in acquired immunodeficiency syndrome (AIDS) patients.

97 n a new host is a critical goal for acquired immunodeficiency syndrome (AIDS) research.

98 Most acquired immunodeficiency syndrome (AIDS) service providers are i

99 isease incidence among persons with acquired immunodeficiency syndrome (AIDS) since the introduction

100 authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 per

101 sociated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility.

102 irus (HIV) among cases who obtained acquired immunodeficiency syndrome (AIDS) through heterosexual co

103 associated with communication about acquired immunodeficiency syndrome (AIDS) through social networks

104 e authors compared 1,642 women with acquired immunodeficiency syndrome (AIDS) to 8,443 uninfected wom

105 monkeys with acute SIV infection or acquired immunodeficiency syndrome (AIDS) underwent normal matura

106 -based natural-history cohorts with acquired immunodeficiency syndrome (AIDS) were genotyped for 21 s

107 us (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are receiving highl

108 ptosporidiosis in patients with the acquired immunodeficiency syndrome (AIDS), and went on to study i

109 he likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relation betwe

110 wed from seroconversion to incident acquired immunodeficiency syndrome (AIDS), death, or the beginnin

111 type 1 (HIV-1), the cause of human acquired immunodeficiency syndrome (AIDS), is a zoonotic infectio

112 rus type 1 (HIV-1) infection to the acquired immunodeficiency syndrome (AIDS), it appears that the st

113 o measure, as a model of wasting in acquired immunodeficiency syndrome (AIDS), longitudinal body-comp

114 luded in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining canc

115 prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the case repr

116 deaths among people diagnosed with acquired immunodeficiency syndrome (AIDS), the authors determined

117 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis (TB), and

118 e activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated the assoc

119 fection in macaques leads to simian Acquired Immunodeficiency Syndrome (AIDS), which does not happen

120 troviral therapy, which can prevent acquired immunodeficiency syndrome (AIDS)-associated events, rest

121 Patients with acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin

122 IV)-infected macaques as a model of acquired immunodeficiency syndrome (AIDS)-associated P. carinii p

123 The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses hu

124 Histoplasmosis is among the main acquired immunodeficiency syndrome (AIDS)-defining conditions in

125 d by disease severity defined as an acquired immunodeficiency syndrome (AIDS)-defining event or low C

126 n of LTF on estimated rates of LTF, acquired immunodeficiency syndrome (AIDS)-defining events, and de

127 Ten individuals developed acquired immunodeficiency syndrome (AIDS)-defining events.

128 have a new (previously undiagnosed) acquired immunodeficiency syndrome (AIDS)-defining illness at 48

129 roviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illnesses rema

130 ; all were antiretroviral-naive and acquired immunodeficiency syndrome (AIDS)-free prior to their fir

131 y CD4(+) levels associated with the acquired immunodeficiency syndrome (AIDS)-free time equivalent to

132 We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) event

133 r investigating the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related cytopenias.

134 rmine whether microbiologic cure of acquired immunodeficiency syndrome (AIDS)-related disseminated cr

135 iency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnesses to ch

136 study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma

137 nt in the early pathogenesis of the acquired immunodeficiency syndrome (AIDS)-related lymphoma (ARL).

138 ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and n

139 time-varying incident TB on time to acquired immunodeficiency syndrome (AIDS)-related mortality using

140 atric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency

141 n since the earliest recognition of acquired immunodeficiency syndrome (AIDS).

142 lopment of a preventive vaccine for acquired immunodeficiency syndrome (AIDS).

143 virus (SIV) very rarely progress to acquired immunodeficiency syndrome (AIDS).

144 nal increases in incidence rates of acquired immunodeficiency syndrome (AIDS).

145 tunistic infection of patients with acquired immunodeficiency syndrome (AIDS).

146 nfection in untreated patients with acquired immunodeficiency syndrome (AIDS).

147 and its predictors in children with acquired immunodeficiency syndrome (AIDS).

148 e chronic diarrhea in patients with acquired immunodeficiency syndrome (AIDS).

149 degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS).

150 ne as a cofactor for development of acquired immunodeficiency syndrome (AIDS).

151 inal disease are common features of acquired immunodeficiency syndrome (AIDS).

152 retinitis in 160 patients with the acquired immunodeficiency syndrome (AIDS).

153 nes in morbidity and mortality from acquired immunodeficiency syndrome (AIDS).

154 Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome (AIDS).

155 target for design of drugs against acquired immunodeficiency syndrome (AIDS).

156 factor in the immunopathogenesis of acquired immunodeficiency syndrome (AIDS).

157 infectivity and the progression to acquired immunodeficiency syndrome (AIDS).

158 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

159 ation of pneumonia in patients with acquired immunodeficiency syndrome (AIDS).

160 adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS).

161 transmitted diseases, including the acquired immunodeficiency syndrome (AIDS).

162 loads and more rapid progression to acquired immunodeficiency syndrome (AIDS).

163 ction, is a principal driver of the acquired immunodeficiency syndrome (AIDS).

164 dity and mortality in patients with acquired immunodeficiency syndrome (AIDS).

165 orce of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS).

166 HIV-1 infection and progression to acquired immunodeficiency syndrome (AIDS).

167 tomach and esophagus in people with acquired immunodeficiency syndrome (AIDS).

168 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS).

169 s-specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS).

170 n (rIFN)- gamma 1b in patients with acquired immunodeficiency syndrome and acute cryptococcal meningi

171 ture isolates from 87 patients with acquired immunodeficiency syndrome and CMV retinitis who received

172 stance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis.

173 an increased risk of progression to acquired immunodeficiency syndrome and death, a relationship that

174 assically reported in patients with acquired immunodeficiency syndrome and emerged as a cause of pers

175 lcohol consumption (one of whom had acquired immunodeficiency syndrome and hepatitis B), one was posi

176 ical parameters among patients with acquired immunodeficiency syndrome and histoplasmosis in Brazil a

177 ted by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious diseases,

178 uman immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.

179 incarceration and reported cases of acquired immunodeficiency syndrome and syphilis were weak (r=0.20

180 PIDs increases as researchers discover novel immunodeficiency syndromes and as clinicians increasingl

181 egulated expression is associated with human immunodeficiency syndromes and vascular integrity, it is

182 Emerging evidence indicates that innate immunodeficiency syndromes are linked to mutations in in

183 accumulation relevant to a broad variety of immunodeficiency syndromes as well as to diseases and di

184 tivate Artemis cause a human severe combined immunodeficiency syndrome associated with cellular radio

185 sregulation (PLAID) is a newly characterized immunodeficiency syndrome associated with distinct cutan

186 are responsible for a rare primary combined immunodeficiency syndrome associated with severe cutaneo

187 Novel immunodeficiency syndromes associated with mutations in

188 tal infection, transplantation, and acquired immunodeficiency syndrome-associated CMV diseases.

189 the disease burden in patients with acquired immunodeficiency syndrome-associated tuberculosis.

190 n syndrome has been proposed to be a primary immunodeficiency syndrome because of the high frequency

191 Records of people diagnosed with acquired immunodeficiency syndrome between 1993 and 2007 in Flori

192 alignancy, storage diseases, BM failure, and immunodeficiency syndromes between 1991 and 1999.

193 's first case involving HIV and the acquired immunodeficiency syndrome, Bragdon v Abbott, addressed t

194 d-Specific)/Lsh in human DNA causes a severe immunodeficiency syndrome, but the nature of the defect

195 TB accelerates acquired immunodeficiency syndrome by increasing human immunodefi

196 ion and is defective in the human hereditary immunodeficiency syndrome called bare lymphocyte syndrom

197 troviral inoculum, LP-BM5, which produces an immunodeficiency syndrome called murine AIDS (MAIDS).

198 etiologic defective virus (BM5def) causes an immunodeficiency syndrome called murine AIDS (MAIDS).

199 package of services provided by HIV/acquired immunodeficiency syndrome care and treatment programs in

200 allelic IRF8 deficiency, revealing a complex immunodeficiency syndrome caused by DC and monocyte defi

201 in 6 patients with a newly described genetic immunodeficiency syndrome caused by mutations in GATA2-a

202 na) with one isolate of SIVagm results in an immunodeficiency syndrome characterized by progressive C

203 Haploinsufficiency for GATA2 causes human immunodeficiency syndromes characterized by mycobacteria

204 tates effective newborn screening for severe immunodeficiency syndromes characterized by the absence

205 ional Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P106

206 rolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group.

207 ere participants in the Multicenter Acquired Immunodeficiency Syndrome Cohort Study for GBV-C viremia

208 differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse eve

209 )/L and 549 x 10(6)/L without prior acquired immunodeficiency syndrome-defining conditions receiving

210 reas patients who developed another acquired immunodeficiency syndrome-defining illness did not.

211 ed to determine predictors of a new acquired immunodeficiency syndrome-defining illness or death.

212 focal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness.

213 and CIN, and cervical cancer is an acquired immunodeficiency syndrome-defining illness.

214 percent of the patients had had an acquired immunodeficiency syndrome-defining illness.

215 function and presents clinically as acquired immunodeficiency syndrome dementia complex (ADC).

216 munodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had R5 tropis

217 NTS, including autoimmune diseases, acquired immunodeficiency syndrome, diabetes, cirrhosis, transpla

218 The proportion of acquired immunodeficiency syndrome diagnoses in which wasting was

219 Having an acquired immunodeficiency syndrome diagnosis or multiple Salmonel

220 netic association with HIV-1 and/or acquired immunodeficiency syndrome disease progression in an Afri

221 The findings define a new X-linked recessive immunodeficiency syndrome, distinct from other types of

222 nal caspase-8 in T cells manifest a profound immunodeficiency syndrome due to defective T cell antige

223 ical presentation in the era of the acquired immunodeficiency syndrome epidemic.

224 1 (HIV-1) and those affected by the acquired immunodeficiency syndrome epidemic.

225 2 ALIVE scientists and an expert in acquired immunodeficiency syndrome epidemiology about the relatio

226 l therapeutic target to prevent non-acquired immunodeficiency syndrome events.

227 s attending a county outpatient HIV/acquired immunodeficiency syndrome facility were referred for the

228 , regarding estimation of long-term acquired immunodeficiency syndrome-free survival to demonstrate t

229 Genetic identification of immunodeficiency syndromes has become more efficient wit

230 link between autoimmune diseases and primary immunodeficiency syndromes has been increasingly appreci

231 on-gamma (IFN-gamma) autoantibody-associated immunodeficiency syndrome have been reported, its natura

232 the incidence of and mortality from acquired immunodeficiency syndrome have declined recently in the

233 als both positive and negative for the human immunodeficiency syndrome (HIV) in the Multicenter AIDS

234 an immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) (OR = 4.27; CI, 1.5

235 led-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment

236 Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is one of the leadi

237 betes, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), arthritis, inflamm

238 or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illnes

239 BM5 murine leukemia virus causes an acquired immunodeficiency syndrome in C57BL/6 mice (MAIDS) and im

240 is often the first manifestation of acquired immunodeficiency syndrome in patients infected with huma

241 Human immunodeficiency syndrome infection was more common in O

242 biallelic mutations in VPS45 underlies a new immunodeficiency syndrome involving impaired neutrophil

243 dominant forms of the hyper-IgE syndrome, an immunodeficiency syndrome involving increased innate imm

244 on-gamma (IFN-gamma) autoantibody-associated immunodeficiency syndrome is not well understood.

245 HIV-2, a human pathogen that causes acquired immunodeficiency syndrome, is distinct from the more pre

246 hown that DOCK8, a gene mutated in a primary immunodeficiency syndrome, is involved in NK cell killin

247 duces the mortality of persons with acquired immunodeficiency syndrome, it does not eliminate HIV res

248 ction drug users recruited into the Acquired Immunodeficiency Syndrome Link to Intravenous Experience

249 In nonhuman primate models of acquired immunodeficiency syndrome, live attenuated lentiviruses

250 Since mice with retrovirus-induced immunodeficiency syndrome (MAIDS) exhibited a frequency

251 odeficiency virus infection and the acquired immunodeficiency syndrome, medical malpractice, and the

252 The immunodeficiency syndrome murine AIDS (MAIDS), caused by

253 Deaths from acquired immunodeficiency syndrome occurred exclusively among pro

254 morphic Artemis mutations result in combined immunodeficiency syndromes of varying severity, but, in

255 ate therapy prior to progression to acquired immunodeficiency syndrome or death by both measures of a

256 pout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing use of high

257 antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors combined

258 tiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 dropped out.

259 s with human immunodeficiency virus/acquired immunodeficiency syndrome or substance abuse (family pra

260 8-0.57) and increased with comorbid acquired immunodeficiency syndrome (OR 4.52, CI 3.01-6.79).

261 begun to mitigate the impact of the acquired immunodeficiency syndrome pandemic.

262 r has become increasingly common in acquired immunodeficiency syndrome patients but has only rarely b

263 l cord dorsal horn (SDH) from HIV-1/acquired immunodeficiency syndrome patients who developed chronic

264 s with human immunodeficiency virus/acquired immunodeficiency syndrome, patients receiving therapeuti

265 erologic diagnosis of HIV, from the acquired immunodeficiency syndrome program of the Health Center o

266 eningitis accounts for 20 to 25% of acquired immunodeficiency syndrome-related deaths in Africa.

267 5% of patients with newly diagnosed acquired immunodeficiency syndrome-related lymphoma (ARL).

268 terologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from a CCR5(-

269 The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has i

270 Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are largely

271 to evaluate the effect of HAART on acquired immunodeficiency syndrome-related mortality, adjusting f

272 ecause the incidence of traditional acquired immunodeficiency syndrome-related opportunistic infectio

273 tween HCV and MI in the Centers for Acquired Immunodeficiency Syndrome Research Network of Integrated

274 mmunodeficiency virus infection and acquired immunodeficiency syndrome, rheumatoid arthritis, and hem

275 on has on the progression of simian acquired immunodeficiency syndrome (SAIDS).

276 The mean reporting completeness for acquired immunodeficiency syndrome, sexually transmitted diseases

277 murine retroviral isolate, develop a severe immunodeficiency syndrome similar to that in humans infe

278 with the dedicator of cytokinesis 8 (DOCK8) immunodeficiency syndrome suffer from recurrent viral an

279 is not integrated into routine HIV/acquired immunodeficiency syndrome surveillance in the United Sta

280 uces a complex disease featuring an acquired immunodeficiency syndrome termed murine AIDS (MAIDS) in

281 ed by slower disease progression to acquired immunodeficiency syndrome than results from HIV-1 infect

282 In acquired immunodeficiency syndrome, the retina is a major site of

283 major problem in patients with the acquired immunodeficiency syndrome, the specific microbial and ho

284 virus (HIV) protease inhibitors in acquired immunodeficiency syndrome therapy.

285 n era (using data from the European Acquired Immunodeficiency Syndrome Treatment Network [NEAT]).

286 dwide health problems caused by the acquired immunodeficiency syndrome, tuberculosis, and malaria, it

287 of their epitopes in the design of acquired immunodeficiency syndrome vaccines.

288 measles in the setting of a chronic acquired immunodeficiency syndrome virus infection.

289 used to clarify the distribution of acquired immunodeficiency syndrome virus-specific cytotoxic T lym

290 ficiency disease veno-occlusive disease with immunodeficiency syndrome (VODI), which is characterized

291 10% and a positive association with acquired immunodeficiency syndrome were borderline significant (P

292 lymphoma, severe liver disease, and acquired immunodeficiency syndrome were rarely identified among p

293 f brain tissue from 2 patients with acquired immunodeficiency syndrome who had CMV encephalitis showe

294 immune restoration in patients with acquired immunodeficiency syndrome who have incomplete responses

295 e describe and define a novel CSA and B-cell immunodeficiency syndrome with additional features resem

296 stic syndrome, acute myeloid leukemia and an immunodeficiency syndrome with complex phenotypes includ

297 imelight because it can be linked to primary immunodeficiency syndromes with autoimmunity.

298 a, and human immunodeficiency virus/acquired immunodeficiency syndrome, with significant results.

299 ytes/mm(3)), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years.

300 inked agammaglobulinemia and murine X-linked immunodeficiency syndrome (xid).